{"doi":"10.1016/j.neuropharm.2009.06.018","title":"Oxytocin decreases methamphetamine self-administration, methamphetamine hyperactivity, and relapse to methamphetamine-seeking behaviour in rats","abstract":null,"journal":"Neuropharmacology","year":2010,"id":642953,"datarank":0.7475409932562506,"base_score":4.983606621708336,"endowment":4.983606621708336,"self_citation_contribution":0.7475409932562506,"citation_network_contribution":0.0,"self_endowment_contribution":0.7475409932562506,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":145,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1122550,"name":"Jennifer L. Cornish","orcid":"0000-0002-9754-8069","position":1,"is_corresponding":false},{"id":1672665,"name":"Adam J. Guastella","orcid":null,"position":2,"is_corresponding":false},{"id":1511072,"name":"Glenn E. Hunt","orcid":null,"position":3,"is_corresponding":false},{"id":409017,"name":"Iain S. McGregor","orcid":"0000-0002-9307-7159","position":4,"is_corresponding":false},{"id":1672664,"name":"Dean S. Carson","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Oxytocin decreases methamphetamine self-administration, methamphetamine hyperactivity, and relapse to methamphetamine-seeking behaviour in rats","abstract":"There is emerging evidence that the neuropeptide oxytocin may be utilised as a treatment for various psychopathologies, including drug addictions. Here we used an animal model to assess whether oxytocin might be effective in the treatment of methamphetamine addiction. Sprague-Dawley rats were trained to lever press to intravenously self-administer methamphetamine under a progressive ratio schedule of reinforcement. Once responding had stabilised, one group of rats received escalating doses of oxytocin (0.001, 0.01, 0.1, 0.3, 1 mg/kg) administered intraperitoneally (IP) prior to daily self-administration tests, while other rats received vehicle. After these tests, lever-pressing was extinguished and the ability of methamphetamine primes (IP, 1 mg/kg) to reinstate responding was studied with and without co-administration of oxytocin (IP, 0.3 and 1 mg/kg). Results showed that oxytocin dose-dependently reduced responding for intravenous methamphetamine with an almost complete absence of responding at the highest oxytocin dose (1 mg/kg). Hyperactivity during methamphetamine self-administration was also dose-dependently reduced by oxytocin. Oxytocin (1 but not 0.3 mg/kg) also reduced the ability of methamphetamine to reinstate methamphetamine-seeking behaviour. In separate tests, oxytocin (IP, 0.3 and 1 mg/kg) robustly decreased the hyperactivity and rearing induced by methamphetamine challenge (IP, 1 mg/kg), producing activity levels similar to control animals. This study suggests that oxytocin may have a powerful inhibitory effect on the motivation to consume methamphetamine and on hyperactivity associated with acute methamphetamine intoxication. These results point to the potential utility of human trials of oxytocin as a therapeutic treatment for methamphetamine addiction.","is_dataset_classified":null,"base_score":4.983606621708336,"endowment":4.983606621708336,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"19560473","pmcid":null,"openalex_id":"https://openalex.org/W1985605151","authors":[],"funders":[],"total_grants":0,"fwci":6.0514,"citation_percentile":0.9581768,"influential_citations":0,"citation_trend":[{"year":2012,"count":8},{"year":2013,"count":15},{"year":2014,"count":9},{"year":2015,"count":14},{"year":2016,"count":14},{"year":2017,"count":13},{"year":2018,"count":12},{"year":2019,"count":18},{"year":2020,"count":9},{"year":2021,"count":8},{"year":2022,"count":6},{"year":2023,"count":3},{"year":2024,"count":4},{"year":2025,"count":2}],"oa_status":"closed","license":"https://www.elsevier.com/tdm/userlicense/1.0/","oa_locations":[{"url":"https://api.elsevier.com/content/article/PII:S0028390809001750?httpAccept=text/xml","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S0028390809001750?httpAccept=text/plain","host_type":"publisher"},{"url":"https://doi.org/10.1016/j.neuropharm.2009.06.018","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/19560473","host_type":"repository"}],"fields_of_study":["Neuroendocrine regulation and behavior","Evolutionary Psychology and Human Behavior","Neurotransmitter Receptor Influence on Behavior","Amphetamine-Related Disorders","Analysis of Variance","Animals","Behavior, Animal","Central Nervous System Stimulants","Conditioning, Operant","Dose-Response Relationship, Drug","Male","Methamphetamine","Motor Activity","Oxytocics","Oxytocin","Rats","Rats, Sprague-Dawley","Reinforcement Schedule","Self Administration"],"mesh_terms":["Central Nervous System Stimulants","Analysis of Variance","Animals","Behavior, Animal","Conditioning, Operant","Dose-Response Relationship, Drug","Male","Methamphetamine","Motor Activity","Oxytocics","Oxytocin","Reinforcement Schedule","Self Administration","Rats, Sprague-Dawley","Amphetamine-Related Disorders","Rats"],"keywords":["Methamphetamine","Oxytocin","Self-administration","Pharmacology","Addiction","Medicine","Psychology","Endocrinology","Psychiatry"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-08T11:09:22.055907Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}